TY  - JOUR
AU  - Ignjatović, Svetlana
AU  - Majkić-Singh, Nada
AU  - Radenković, Dejan
AU  - Gvozdenović, Miomir
AU  - Mitrović, Mihajlo
PY  - 2004
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/557
AB  - Severe pancreatitis occurs in 20%’30% of all patients with acute pancreatitis. Pancreatic enzymes, cytokines and other active peptides, liberated from the inflamed pancreas, convert inflammation of the pancreas as a single-organ disease of the retroperitoneum to a multisystem disease. Determinations of pancreatic serum enzymes are still "the golden standard" for diagnosis of the acute pancreatitis. Out of clinically significant pancreatic enzymes, pancreatic-amylase and lipase are suggested for routine clinical determination due to available methods for their measurement. The methods are simple, and the results may be obtained rather quickly without any special equipment. Maximal diagnostic accuracy is achieved by "cut-off" values of 182 U/L for pancreatic-amylase and 656 U/L for lipase. Treatment of patients with acute pancreatitis is based on the initial assessment of disease severity. Early staging is based on the presence and degree of systemic failure (cardiovascular, pulmonary, and renal) and on the presence and extent of pancreatic necrosis. Individual clinical parameters and laboratory biomarkers, although sometimes helpful, are not sufficiently accurate to reliable assess the severity of an acute attack. Numeric grading systems with sensitivities of about 70% are commonly used today as indicators of organ failure and disease severity. Contrast material-enhanced computed tomography is used in addition to help evaluate local pancreatic morphology and the presence and extent of pancreatic necrosis. Out of all recently studied biochemical parameters for prognostic evaluation of acute pancreatitis patients, the measurement of C-reactive protein concentration appeared to be the parameter with the highest clinical accuracy. The best differentiation of moderate from severe acute pancreatitis forms is achieved by "cut-off" CRP values of 126 mg/L, 48 hours from the onset of symptoms. For this reason, CRP measurement may be used as the alternative to computerized tomography. In compliance with the postulations for evidence- based medicine, the procedures related to diagnosis, prognosis and management of acute pancreatitis are classified into four categories: certain, probable, possible and inappropriate.
AB  - Težak oblik bolesti se javlja kod 20%’30% pacijenata sa akutnim pankreatitisom. Oslobađanje pankreasnih enzima, citokina i drugih aktivnih peptide iz pankreasa zahvaćenog inflamacijom uzrokuje prelaz od zapaljenja jednog organa u retroperitoneumu ka multisistemskom oboljenju. Određivanje pankreasnih enzima u serumu još uvek ostaje "zlatan standard" u dijagnozi akutnog pankreatitisa. Od klinički važnih pankreasnih enzima za kliničko rutinsko određivanje preporučuju se pankreasna a-amilaza i lipaza zbog postojanja raspoloživih metoda za njihovo određivanje. Metode su jednostavne, rezultat može da se dobije dosta brzo i ne zahteva posebnu opremu za određivanje. Maksimalna dijagnostička tačnost se postiže pri "cut-off" vrednostima od 182 U/L za pankreasnu a-amilazu i 656 U/L za lipazu. Tretman pacijenata sa akutnim pankreatitisom se zasniva na inicijalnoj proceni težine oboljenja. Rana gradacija se zasniva na prisustvu i stepenu sistemskih oštećenja (kardiovasdkularnih, pulmonalnih i renalnih), kao i na prisustvu i veličini pankreasne nekroze. Mada individualni klinički parametri i laboratorijski biomarkeri mogu da budu od pomoći, to nije dovoljno tačno u proceni težine napada. Brojni "sistemi scorova" koriste se danas kao indikatori oštećenja organa i težine oboljenja i njihova osetljivost iznosi oko 70%. Kompjuterizovana tomografija poboljšana kontrastom se koristi za dodatnu evaluaciju lokalne pankreasne morfologije, kao i stepena pankreasne nekroze. Od svih do sada ispitivanih biohemijskih parametara za prognostičku evaluaciju pacijenata sa akutnim pankreatitisom, određivanje koncentracije C-reaktivnog proteina (CRP) predstavlja parametar sa najvećom kliničkom tačnošću. Najbolje razlikovanje blagih od teških oblika AP se postiže pri "cut-off" vrednosti CRP od 126 mg/L i to 48 sati od početka simptoma. Iz ovih razloga određivanje CRP može da se koristi kao alternativa kompjuterizovanoj tomografiji. U skladu sa postulatima na kojima se zasniva medicina zasnovana na dokazima (eng. evidence-based medicine) postupci vezani za prognozu i tretman akutnog pankreatitisa se klasifikuju u četiri kategorije: izvesni, verovatni, mogući i neodgovarajući.
PB  - Društvo medicinskih biohemičara Srbije i Crne Gore, Beograd i Univerzitet u Beogradu - Farmaceutski fakultet, Beograd
T2  - Jugoslovenska medicinska biohemija
T1  - Diagnosis, assessment of severity and management of acute pancreatitis
T1  - Dijagnoza, procena težine i menadžment akutnog pankreatitisa
VL  - 23
IS  - 3
SP  - 229
EP  - 233
DO  - 10.2298/JMH0403229I
ER  - 

@article{
author = "Ignjatović, Svetlana and Majkić-Singh, Nada and Radenković, Dejan and Gvozdenović, Miomir and Mitrović, Mihajlo",
year = "2004",
abstract = "Severe pancreatitis occurs in 20%’30% of all patients with acute pancreatitis. Pancreatic enzymes, cytokines and other active peptides, liberated from the inflamed pancreas, convert inflammation of the pancreas as a single-organ disease of the retroperitoneum to a multisystem disease. Determinations of pancreatic serum enzymes are still "the golden standard" for diagnosis of the acute pancreatitis. Out of clinically significant pancreatic enzymes, pancreatic-amylase and lipase are suggested for routine clinical determination due to available methods for their measurement. The methods are simple, and the results may be obtained rather quickly without any special equipment. Maximal diagnostic accuracy is achieved by "cut-off" values of 182 U/L for pancreatic-amylase and 656 U/L for lipase. Treatment of patients with acute pancreatitis is based on the initial assessment of disease severity. Early staging is based on the presence and degree of systemic failure (cardiovascular, pulmonary, and renal) and on the presence and extent of pancreatic necrosis. Individual clinical parameters and laboratory biomarkers, although sometimes helpful, are not sufficiently accurate to reliable assess the severity of an acute attack. Numeric grading systems with sensitivities of about 70% are commonly used today as indicators of organ failure and disease severity. Contrast material-enhanced computed tomography is used in addition to help evaluate local pancreatic morphology and the presence and extent of pancreatic necrosis. Out of all recently studied biochemical parameters for prognostic evaluation of acute pancreatitis patients, the measurement of C-reactive protein concentration appeared to be the parameter with the highest clinical accuracy. The best differentiation of moderate from severe acute pancreatitis forms is achieved by "cut-off" CRP values of 126 mg/L, 48 hours from the onset of symptoms. For this reason, CRP measurement may be used as the alternative to computerized tomography. In compliance with the postulations for evidence- based medicine, the procedures related to diagnosis, prognosis and management of acute pancreatitis are classified into four categories: certain, probable, possible and inappropriate., Težak oblik bolesti se javlja kod 20%’30% pacijenata sa akutnim pankreatitisom. Oslobađanje pankreasnih enzima, citokina i drugih aktivnih peptide iz pankreasa zahvaćenog inflamacijom uzrokuje prelaz od zapaljenja jednog organa u retroperitoneumu ka multisistemskom oboljenju. Određivanje pankreasnih enzima u serumu još uvek ostaje "zlatan standard" u dijagnozi akutnog pankreatitisa. Od klinički važnih pankreasnih enzima za kliničko rutinsko određivanje preporučuju se pankreasna a-amilaza i lipaza zbog postojanja raspoloživih metoda za njihovo određivanje. Metode su jednostavne, rezultat može da se dobije dosta brzo i ne zahteva posebnu opremu za određivanje. Maksimalna dijagnostička tačnost se postiže pri "cut-off" vrednostima od 182 U/L za pankreasnu a-amilazu i 656 U/L za lipazu. Tretman pacijenata sa akutnim pankreatitisom se zasniva na inicijalnoj proceni težine oboljenja. Rana gradacija se zasniva na prisustvu i stepenu sistemskih oštećenja (kardiovasdkularnih, pulmonalnih i renalnih), kao i na prisustvu i veličini pankreasne nekroze. Mada individualni klinički parametri i laboratorijski biomarkeri mogu da budu od pomoći, to nije dovoljno tačno u proceni težine napada. Brojni "sistemi scorova" koriste se danas kao indikatori oštećenja organa i težine oboljenja i njihova osetljivost iznosi oko 70%. Kompjuterizovana tomografija poboljšana kontrastom se koristi za dodatnu evaluaciju lokalne pankreasne morfologije, kao i stepena pankreasne nekroze. Od svih do sada ispitivanih biohemijskih parametara za prognostičku evaluaciju pacijenata sa akutnim pankreatitisom, određivanje koncentracije C-reaktivnog proteina (CRP) predstavlja parametar sa najvećom kliničkom tačnošću. Najbolje razlikovanje blagih od teških oblika AP se postiže pri "cut-off" vrednosti CRP od 126 mg/L i to 48 sati od početka simptoma. Iz ovih razloga određivanje CRP može da se koristi kao alternativa kompjuterizovanoj tomografiji. U skladu sa postulatima na kojima se zasniva medicina zasnovana na dokazima (eng. evidence-based medicine) postupci vezani za prognozu i tretman akutnog pankreatitisa se klasifikuju u četiri kategorije: izvesni, verovatni, mogući i neodgovarajući.",
publisher = "Društvo medicinskih biohemičara Srbije i Crne Gore, Beograd i Univerzitet u Beogradu - Farmaceutski fakultet, Beograd",
journal = "Jugoslovenska medicinska biohemija",
title = "Diagnosis, assessment of severity and management of acute pancreatitis, Dijagnoza, procena težine i menadžment akutnog pankreatitisa",
volume = "23",
number = "3",
pages = "229-233",
doi = "10.2298/JMH0403229I"
}

Ignjatović, S., Majkić-Singh, N., Radenković, D., Gvozdenović, M.,& Mitrović, M.. (2004). Diagnosis, assessment of severity and management of acute pancreatitis. in Jugoslovenska medicinska biohemija
Društvo medicinskih biohemičara Srbije i Crne Gore, Beograd i Univerzitet u Beogradu - Farmaceutski fakultet, Beograd., 23(3), 229-233.
https://doi.org/10.2298/JMH0403229I

Ignjatović S, Majkić-Singh N, Radenković D, Gvozdenović M, Mitrović M. Diagnosis, assessment of severity and management of acute pancreatitis. in Jugoslovenska medicinska biohemija. 2004;23(3):229-233.
doi:10.2298/JMH0403229I .

Ignjatović, Svetlana, Majkić-Singh, Nada, Radenković, Dejan, Gvozdenović, Miomir, Mitrović, Mihajlo, "Diagnosis, assessment of severity and management of acute pancreatitis" in Jugoslovenska medicinska biohemija, 23, no. 3 (2004):229-233,
https://doi.org/10.2298/JMH0403229I . .

TY  - CONF
AU  - Ignjatović, Svetlana
AU  - Majkić-Singh, Nada
AU  - Gvozdenović, Miomir
AU  - Mitrović, Mihajlo
PY  - 2002
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/350
AB  - Precise definition of the most significant states of the acute pancreatitis (AP) is a must for enabling the early diagnosis and adequate treatment of patient. AP is a heterogenous disease manifested by moderately circumscribed condition to very severe and progressive condition followed by major and progressive complications, and even lethal outcome. Further clinical treatment of patients depends upon the nature of pancreatic lesion and should be based on the appropriate prognostic evaluation. Unfortunately, there has not been yet a perfect system or biochemical marker for accurate estimation of AP severity. In compliance with the postulations for evidence-based medicine, the procedures related to prognosis and treatment of AP are classified into four categories: certain, probable, possible and inappropriate. Laboratory tests used for AP diagnosis are based on determination of pancreatic secretory products and different components of body fluids, which probably reflect the presence and degree of inflammatory alterations of pancreas as well as the effects to the organism. Determinations of pancreatic serum enzymes are still „the golden standard” for diagnosis of the acute pancreatitis. Out of clinically significant pancreatic enzymes, pancreatic alfa-amylase and lipase are suggested for routine clinical determination due to available methods for their measurement. The methods are simple, and the results may be obtained rather quickly without any special equipment. Maximal diagnostic accuracy is achieved by „cut-off” values of 182 U/L for pancreatic alfa-amylase and 656 U/L for lipase. Clinical recognition of patients with severe attack is not reliable at admission of patients and it is more conclusive after two to three days. Out of all recently studied biochemical parameters for prognostic evaluation of AP patients, the measurement of C-reactive protein (CRP) concentration appeared to be the parameter with the highest clinical accuracy. The best differentiation of moderate from severe AP forms is achieved by „cut-off” CRP values of 126 mg/L, 48 hours from the onset of symptoms. For this reason, CRP measurement may be used as the alternative to computerized tomography in differentiation of edematous from necrotic AP.
AB  - Precizno definisanje najvažnijih stanja akutnog pankreatitisa (AP) neophodno je za ranu prognozu i odgovarajući tretman pacijenata. AP je heterogeno oboljenje koje se manifestuje od blago ograničenog oboljenja do vrlo teškog i progresivnog stanja koje mogu da prate velike i progresivne komplikacije, pa i smrt. Dalji klinički tretman pacijenata zavisi od prirode pankreasne lezije i treba da se zasniva na odgovarajućoj prognostičkoj evaluaciji. Na žalost, još uvek ne postoji idealan sistem ili biohemijski marker kojim bi se tačno predvidela težina AP. U skladu sa postulatima na kojima se zasniva medicina zasnovana na dokazima (eng. evidence-based medicine) postupci vezani za prognozu i tretman AP klasifikuju se kao izvesni, verovatni, mogući i neodgovarajući. Laboratorijska ispitivanja koja se koriste za dijagnozu AP zasnivaju se na određivanju pankreasnih sekretornih proizvoda i različitih komponenata telesnih tečnosti koji verovatno odražavaju prisustvo i stepen inflamatornih promena u pankreasu, kao i posledica na organizam. Određivanje pankreasnih enzima u serumu još uvek je "zlatan standard" u dijagnozi akutnog pankreatitisa. Od pankreasnih enzima za kliničko rutinsko određivanje preporučuju se pankreasna alfa-amilaza i lipaza zbog postojanja raspoloživih metoda za njihovo određivanje. Metode su jednostavne, rezultat može da se dobije dosta brzo i ne zahteva posebnu opremu za određivanje. Maksimalna dijagnostička tačnost se postiže pri "cut-off" vrednostima od 182 U/L za pankreasnu alfa-amilazu i 656 U/L za lipazu. Kliničko prepoznavanje pacijenata sa teškim napadom je nepouzdano pri prijemu pacijenta i značajno je bolje posle dva do tri dana. Od svih do sada ispitivanih biohemijskih parametara za prognostičku evaluaciju pacijenata sa AP, određivanje koncentracije C-reaktivnog proteina (CRP) je parametar sa najvećom kliničkom tačnošću. Razlikovanje blagih od teških oblika AP se najbolje postiže pri "cut-off" vrednosti CRP od 126 mg/L i to 48 sati od početka simptoma. Iz ovih razloga određivanje CRP može da se koristi kao alternativa kompjuterizovanoj tomografiji u diferenciranju edematoznog od nekrotičnog oblika AP.
PB  - Savez farmaceutskih udruženja Srbije, Beograd
C3  - Arhiv za farmaciju
T1  - Evidence-based medicine: Diagnosis and evaluation of the severity of acute pancreatitis
T1  - Medicina zasnovana na dokazima: dijagnoza i procena težine akutnog pankreatitisa
VL  - 52
IS  - 3
SP  - 327
EP  - 336
UR  - https://hdl.handle.net/21.15107/rcub_farfar_350
ER  - 

@conference{
author = "Ignjatović, Svetlana and Majkić-Singh, Nada and Gvozdenović, Miomir and Mitrović, Mihajlo",
year = "2002",
abstract = "Precise definition of the most significant states of the acute pancreatitis (AP) is a must for enabling the early diagnosis and adequate treatment of patient. AP is a heterogenous disease manifested by moderately circumscribed condition to very severe and progressive condition followed by major and progressive complications, and even lethal outcome. Further clinical treatment of patients depends upon the nature of pancreatic lesion and should be based on the appropriate prognostic evaluation. Unfortunately, there has not been yet a perfect system or biochemical marker for accurate estimation of AP severity. In compliance with the postulations for evidence-based medicine, the procedures related to prognosis and treatment of AP are classified into four categories: certain, probable, possible and inappropriate. Laboratory tests used for AP diagnosis are based on determination of pancreatic secretory products and different components of body fluids, which probably reflect the presence and degree of inflammatory alterations of pancreas as well as the effects to the organism. Determinations of pancreatic serum enzymes are still „the golden standard” for diagnosis of the acute pancreatitis. Out of clinically significant pancreatic enzymes, pancreatic alfa-amylase and lipase are suggested for routine clinical determination due to available methods for their measurement. The methods are simple, and the results may be obtained rather quickly without any special equipment. Maximal diagnostic accuracy is achieved by „cut-off” values of 182 U/L for pancreatic alfa-amylase and 656 U/L for lipase. Clinical recognition of patients with severe attack is not reliable at admission of patients and it is more conclusive after two to three days. Out of all recently studied biochemical parameters for prognostic evaluation of AP patients, the measurement of C-reactive protein (CRP) concentration appeared to be the parameter with the highest clinical accuracy. The best differentiation of moderate from severe AP forms is achieved by „cut-off” CRP values of 126 mg/L, 48 hours from the onset of symptoms. For this reason, CRP measurement may be used as the alternative to computerized tomography in differentiation of edematous from necrotic AP., Precizno definisanje najvažnijih stanja akutnog pankreatitisa (AP) neophodno je za ranu prognozu i odgovarajući tretman pacijenata. AP je heterogeno oboljenje koje se manifestuje od blago ograničenog oboljenja do vrlo teškog i progresivnog stanja koje mogu da prate velike i progresivne komplikacije, pa i smrt. Dalji klinički tretman pacijenata zavisi od prirode pankreasne lezije i treba da se zasniva na odgovarajućoj prognostičkoj evaluaciji. Na žalost, još uvek ne postoji idealan sistem ili biohemijski marker kojim bi se tačno predvidela težina AP. U skladu sa postulatima na kojima se zasniva medicina zasnovana na dokazima (eng. evidence-based medicine) postupci vezani za prognozu i tretman AP klasifikuju se kao izvesni, verovatni, mogući i neodgovarajući. Laboratorijska ispitivanja koja se koriste za dijagnozu AP zasnivaju se na određivanju pankreasnih sekretornih proizvoda i različitih komponenata telesnih tečnosti koji verovatno odražavaju prisustvo i stepen inflamatornih promena u pankreasu, kao i posledica na organizam. Određivanje pankreasnih enzima u serumu još uvek je "zlatan standard" u dijagnozi akutnog pankreatitisa. Od pankreasnih enzima za kliničko rutinsko određivanje preporučuju se pankreasna alfa-amilaza i lipaza zbog postojanja raspoloživih metoda za njihovo određivanje. Metode su jednostavne, rezultat može da se dobije dosta brzo i ne zahteva posebnu opremu za određivanje. Maksimalna dijagnostička tačnost se postiže pri "cut-off" vrednostima od 182 U/L za pankreasnu alfa-amilazu i 656 U/L za lipazu. Kliničko prepoznavanje pacijenata sa teškim napadom je nepouzdano pri prijemu pacijenta i značajno je bolje posle dva do tri dana. Od svih do sada ispitivanih biohemijskih parametara za prognostičku evaluaciju pacijenata sa AP, određivanje koncentracije C-reaktivnog proteina (CRP) je parametar sa najvećom kliničkom tačnošću. Razlikovanje blagih od teških oblika AP se najbolje postiže pri "cut-off" vrednosti CRP od 126 mg/L i to 48 sati od početka simptoma. Iz ovih razloga određivanje CRP može da se koristi kao alternativa kompjuterizovanoj tomografiji u diferenciranju edematoznog od nekrotičnog oblika AP.",
publisher = "Savez farmaceutskih udruženja Srbije, Beograd",
journal = "Arhiv za farmaciju",
title = "Evidence-based medicine: Diagnosis and evaluation of the severity of acute pancreatitis, Medicina zasnovana na dokazima: dijagnoza i procena težine akutnog pankreatitisa",
volume = "52",
number = "3",
pages = "327-336",
url = "https://hdl.handle.net/21.15107/rcub_farfar_350"
}

Ignjatović, S., Majkić-Singh, N., Gvozdenović, M.,& Mitrović, M.. (2002). Evidence-based medicine: Diagnosis and evaluation of the severity of acute pancreatitis. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije, Beograd., 52(3), 327-336.
https://hdl.handle.net/21.15107/rcub_farfar_350

Ignjatović S, Majkić-Singh N, Gvozdenović M, Mitrović M. Evidence-based medicine: Diagnosis and evaluation of the severity of acute pancreatitis. in Arhiv za farmaciju. 2002;52(3):327-336.
https://hdl.handle.net/21.15107/rcub_farfar_350 .

Ignjatović, Svetlana, Majkić-Singh, Nada, Gvozdenović, Miomir, Mitrović, Mihajlo, "Evidence-based medicine: Diagnosis and evaluation of the severity of acute pancreatitis" in Arhiv za farmaciju, 52, no. 3 (2002):327-336,
https://hdl.handle.net/21.15107/rcub_farfar_350 .

TY  - JOUR
AU  - Ignjatović, Svetlana
AU  - Majkić-Singh, Nada
AU  - Mitrović, M.
AU  - Gvozdenović, Miomir
PY  - 2000
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/241
AB  - In this study we determined the clinical accuracy of alpha (2)-macroglobulin, alpha -amylase, C-reactive protein, lipase, non-esterified fatty acids, pancreatic alpha -amylase and phospholipase A in the diagnosis and prognosis of acute pancreatitis in a group of patients with acute abdominal pain using receiver operator characteristic curve analysis. We investigated 59 patients with acute pancreatitis and 72 patients with extrapancreatic diseases of gastrointestinal origin. On the basis of initial enzyme activities, at cut-offs of 245 U/I for amylase. 656 U/I for lipase, and 182 U/I for pancreatic alpha -amylase, the diagnostic efficiencies were 0.993, 0.980, and 0.975, respectively. Receiver operator characteristic curve analysis showed the same diagnostic accuracies. We evaluated the accuracy of serum alpha (2)-macroglobulin, C-reactive protein, non-esterified fatty acids end phospholipase A for differentiation between acute necrotizing pancreatitis and acute oedematous pancreatitis. C-reactive protein had the highest prognostic accuracy of the parameters studied (the area under curve = 0.9082) and at a cut-off value of 126 mg/l, sensitivity and specificity were 0.759 and 0.912, respectively. The role of the clinical laboratory in the investigation of patients with acute pancreatitis continues to evolve and biochemical parameters are a good diagnostic and prognostic: option.
PB  - Walter de Gruyter & Co, Berlin
T2  - Clinical Chemistry and Laboratory Medicine
T1  - Biochemical evaluation of patients with acute pancreatitis
VL  - 38
IS  - 11
SP  - 1141
EP  - 1144
DO  - 10.1515/CCLM.2000.173
ER  - 

@article{
author = "Ignjatović, Svetlana and Majkić-Singh, Nada and Mitrović, M. and Gvozdenović, Miomir",
year = "2000",
abstract = "In this study we determined the clinical accuracy of alpha (2)-macroglobulin, alpha -amylase, C-reactive protein, lipase, non-esterified fatty acids, pancreatic alpha -amylase and phospholipase A in the diagnosis and prognosis of acute pancreatitis in a group of patients with acute abdominal pain using receiver operator characteristic curve analysis. We investigated 59 patients with acute pancreatitis and 72 patients with extrapancreatic diseases of gastrointestinal origin. On the basis of initial enzyme activities, at cut-offs of 245 U/I for amylase. 656 U/I for lipase, and 182 U/I for pancreatic alpha -amylase, the diagnostic efficiencies were 0.993, 0.980, and 0.975, respectively. Receiver operator characteristic curve analysis showed the same diagnostic accuracies. We evaluated the accuracy of serum alpha (2)-macroglobulin, C-reactive protein, non-esterified fatty acids end phospholipase A for differentiation between acute necrotizing pancreatitis and acute oedematous pancreatitis. C-reactive protein had the highest prognostic accuracy of the parameters studied (the area under curve = 0.9082) and at a cut-off value of 126 mg/l, sensitivity and specificity were 0.759 and 0.912, respectively. The role of the clinical laboratory in the investigation of patients with acute pancreatitis continues to evolve and biochemical parameters are a good diagnostic and prognostic: option.",
publisher = "Walter de Gruyter & Co, Berlin",
journal = "Clinical Chemistry and Laboratory Medicine",
title = "Biochemical evaluation of patients with acute pancreatitis",
volume = "38",
number = "11",
pages = "1141-1144",
doi = "10.1515/CCLM.2000.173"
}

Ignjatović, S., Majkić-Singh, N., Mitrović, M.,& Gvozdenović, M.. (2000). Biochemical evaluation of patients with acute pancreatitis. in Clinical Chemistry and Laboratory Medicine
Walter de Gruyter & Co, Berlin., 38(11), 1141-1144.
https://doi.org/10.1515/CCLM.2000.173

Ignjatović S, Majkić-Singh N, Mitrović M, Gvozdenović M. Biochemical evaluation of patients with acute pancreatitis. in Clinical Chemistry and Laboratory Medicine. 2000;38(11):1141-1144.
doi:10.1515/CCLM.2000.173 .

Ignjatović, Svetlana, Majkić-Singh, Nada, Mitrović, M., Gvozdenović, Miomir, "Biochemical evaluation of patients with acute pancreatitis" in Clinical Chemistry and Laboratory Medicine, 38, no. 11 (2000):1141-1144,
https://doi.org/10.1515/CCLM.2000.173 . .